chevron_leftBack
As of 24 April 2025, Northwest Biotherapeutics, Inc. has a market cap of $402.62M USD, ranking #13179 globally and #2428 in the United States. It ranks #1293 in the Healthcare sector, and #353 in the Biotechnology industry.
Key Stats
Market Cap
$402.62MUSD
Enterprise Value
$483.4MUSD
Revenue (TTM)
$1.38MUSD
EBITDA (TTM)
-$64.76MUSD
Net Income (TTM)
-$85.19MUSD
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Linda Powers
open_in_new
Employees
25
Founded
1996
Website
nwbio.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 24% | 43% | 42% | 25% | 28% | -25% |
Upcoming Earnings
Earnings Date
Fri, May 9
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
NWBO
Northwest Biotherapeutics Inc
ISIN: US66737P6007
Shares Out.:
Shares Outstanding:
1.391B1
Shares Float:
1.274B2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
0.3580 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Northwest Biotherapeutics, Inc.
Northwest Biotherapeutics, Inc., a biotechnology company, focuses on developing personalized immune therapies for cancer. The company develops DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer. Its lead product candidate is the DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, that has completed Phase I clinical trials to treat inoperable solid tumors, as well as a range of types of cancers. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.
